Zeisberg A, Seibel I, Cordini D, Lakotka N, Willerding G, Moser L, Heufelder J, Joussen A M
Department of Ophthalmology, Charité University Medicine Berlin, Campus Benjamin Franklin, 12200, Berlin, Germany.
Graefes Arch Clin Exp Ophthalmol. 2014 Jul;252(7):1165-70. doi: 10.1007/s00417-014-2635-1. Epub 2014 Apr 29.
The aim of this retrospective study was to determine the efficacy of proton beam irradiation in choroidal hemangioma in a long-term follow-up.
A total dose of 20 Cobalt Gray equivalent (CGE) was administered to 50 eyes of 50 patients from September 1998 to September 2010. All treated patients presented with a symptomatic tumor. Nine patients were pre-treated by photodynamic therapy (PDT). Visual outcome, tumor regression, and complications resulting from radiation were investigated.
The mean follow-up was 55.4 months (range 13-132). Tumor thickness decreased in all patients. Retinal re-attachment was achieved without evidence of tumor leakage. Visual acuity improved by two lines after one year in 43.4 % of patients and after two years in 36.8 % of patients. During the 55.4 months of long-term follow-up the visual acuity improved from 6/15 to 6/12 after proton therapy. Twenty-three patients (46.0 %) developed radiation retinopathy. According to the Finger classification of 2004, 21 patients (42.0 %) showed a stage 1 or 2 (functionally not relevant) retinopathy, and two patients (4.0 %) presented a stage 3 or 4 (functionally relevant) retinopathy. Further complications included sicca syndrome in nine cases, cataract formation in 10 cases, and radiation optic neuropathy in four cases.
Proton therapy with 20 CGE is an efficient primary therapy in choroidal hemangioma and is very effective as a secondary treatment after PDT.
这项回顾性研究的目的是通过长期随访确定质子束照射治疗脉络膜血管瘤的疗效。
1998年9月至2010年9月期间,对50例患者的50只眼给予了总计20钴灰当量(CGE)的剂量。所有接受治疗的患者均有症状性肿瘤。9例患者曾接受光动力疗法(PDT)预处理。研究了视觉结果、肿瘤消退情况以及放疗引起的并发症。
平均随访时间为55.4个月(范围13 - 132个月)。所有患者的肿瘤厚度均减小。实现了视网膜复位,且无肿瘤渗漏迹象。43.4%的患者在1年后视力提高了两行,36.8%的患者在2年后视力提高。在55.4个月的长期随访期间,质子治疗后视力从6/15提高到了6/12。23例患者(46.0%)发生了放射性视网膜病变。根据2004年的Finger分类,21例患者(42.0%)表现为1期或2期(功能上无相关性)视网膜病变,2例患者(4.0%)表现为3期或4期(功能上有相关性)视网膜病变。其他并发症包括9例干眼症、10例白内障形成以及4例放射性视神经病变。
20 CGE的质子治疗是脉络膜血管瘤有效的一线治疗方法,作为PDT后的二线治疗也非常有效。